Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments

2.1 Ripretinib (Qinlock, Deciphera Pharmaceuticals) is indicated for 'the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib'.

2.2 The dosage schedule is available in the summary of product characteristics for ripretinib.

2.3 The list price of ripretinib is £18,400 per 30‑day supply (excluding VAT; company submission). This is based on a 150‑mg dose once daily (three 50 mg tablets). The company has a commercial arrangement, which would have applied if ripretinib had been recommended.